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Red cell immunization in multiply transfused Malay thalassaemia 
patients. 
Noor Haslina M.N, 1 Ariffin N2, Illuni l-Iayati I, 3 Rosline H. 1 
1Department of 1-letnatology, 1-Iospital University Sains of Malaysia, 2Depa.rtt11ent of 
Paediatric, Hospital University Sains of Malaysia, 3Department of Pathology, Hospital Raja 
Peretnpuan Zainab II, Kota Bharu .. 
ABSTRACTS 
BACKGROUND: The development of red blood cell (RBC) isoitnniunization with 
alloantibodies and autoantibodies cotnplicate transfusion therapy in multiply transfused 
thalassaemia patients. Thus, frequency, causes and prevention of these phenomena were 
studied among these patients. 
STUDY DESIGN AND METHODS: Clinical and serological data of 58 Malay multiply 
transfused thalassaemia patients who seek their treatment in 1-Iospital University Sains 
Malaysia were collected and analyzed prospectively. Blood samples were subjected to 
standard blood bank procedure for screening of antibodies and subsequent antibodies 
identification. All patients in our hospital received blood n1atched for only ABO and Rh 
(D) antigens. 
RESULTS: There were 46 (79.3%) patients with Hb E/f3 thalassactnia~ 8 (13.8%) f3 
thalassaemia major, 3 (5.2%) J-Ib 1-1 Constant Spring and I (1.7%) Hb 1-1 disease. Overall, 
8.6% of the patients had alJoantibodies and 1. 7% had autoantibodies. The alloantibodies 
identified were anti-E, anti-c, anti-K, anti-Jka, anti-N and anti-S. 
CONCLUSION: The transfusion of tnatched blood is essential for chronically nlulti-
transfused patients in order to avoid alloimmunisation. Considering high frequency of anti 
E in our hospital, it is advisable to genotype patients and n1atch the red cell unit for E 
antigens in multiply transfused thalassaemia patients. 
Keywords : Thalassaetnia, allointn1unization, alloantibodies 
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INTI~ODUCTIONS 
Thalassaetnia is one of the tn~or public health problen1s 111 Malaysia. It is a 
heterogeneous group of inherited autosomal recessive disorder of haemoglobin synthesis, 
which is characterized by the absence or reduced output of one or tnore globin chains of 
haemoglobin. 1 
The recommended treatment for thalassaemia ma.Jor involves regular blood 
transfusions, usually administered every 2 to 5 weeks, to maintain the pretransfusion 
haemoglobin level above 9-1 0.5 g/dl. One of the complications of blood transfusion is the 
formation of alloantibodies and autoantibodies against RBC antigen. The results from a 
number of studies have detnonstrated various frequencies and percentages of alloantibody 
and autoantibody formation in multi-transfused patients.2• 3• 5 Some alloantibodies may 
cause haemolytic transfusion reactions and limit the availability of safe transfusion, while 
others are clinically insignificant. Red cell autoantibodies appear less frequent but can 
result in haemolysis and difficulty in blood cross-n1atching.4 
The antibodies must be identified in the recipient's serum before every transfusion 
so that compatible blood can be provided. The causes of alloinm1unisation in thalassaen1ia 
patients are not fully understood, however data suggest that the recipient's immune status, 
absence of spleen and difference in the red cell phenotype between donor and recipients are 
likely to further contributes to the phenomena. 6 This paper reports the result of a study 
carried out in this center to determine the prevalence of RBC aiioantibodies and 
autoantibodies and the factors that might contribute to its development. 
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MATERIALS AND METHODS 
This prospective study was conducted over a 1-year period frotn January 2004 until 
December 2004 at Hospital University Sains Malaysia. The study had been approved by 
the hospital ethical cotnmittees. Written consent was provided. 
Patients 
A total of 58 thalassaetnia patients receiving multiple blood transfusions at interval of 2 to 
4 weeks or had received at least 10 transfusions were included in this study. Diagnosis of 
thalassaemia was confinned by standard haen1oglobin electrophoresis and measuren1ent of 
Hb A, A2 and F. 
Clinical transfusion records of 58 'thalassaetnia patients who fulfilled the criterias 
were analyzed for the presence of allo- and autoimmunization, their antibody specificity 
and the time interval of RBC immunization from start of transfusion. Ethnic background, 
status of splenectomy, age at start of transfusion and the number of blood unit received 
were also recorded. 
Laboratory investigations 
Using standard blood bank n1ethods, serum was analyzed prior to each transfusion 
for detection of new antibody to RBC antigen. All the pretransfusion sera were also tested 
to detennine their phenotype for the following blood group systems namely ABO; Rhesus 
(0, C, E, c, and e); Kell (K, k)~ Kidd (Kpa, Kpb) and Duffy (Fya, Fyb). 
4 
An antigen panel was used for the antibody screening procedure where the serum 
was mixed with saline suspended red cells in LISS Coombs gel card incubat~d at 3 7 oc for 
15 minutes. The antibody identification test was performed by a commercial RBC panel 
when the antibody-screening test was positive. 
Polyspecific direct antiglobulin test was performed using 0.8% cell suspension of 
patient's RBC with anti hutnan globulin. Elution and absorption methods were employed 
in patients with suspected autoantibody. Commercial RBC panel was used for the eluates 
and adsorbed sera to detect any specificity of the autoantibodies and alloantibodics 
respectively. The entire tests were done by using gel card method by Diamed ID 
(Switzerland). 
Statistical Analysis. 
Descriptive statistics and Fischer exact statistical test was perfonned and p value of less 
than 0.05 is considered significant. The results were analyzed using SPSS statistical 
software version 11.0 
RESULTS 
A total of 58 n1ultiply transfused thalassaetnia patients were included in this study. 
Demographic data is as shown in table I. Twenty-two patients (37.9%) were blood group 
B, 16 (27.6%) were blood group 0, 12 (20.7%) were blood group A and 8 (13.8o/o) were 
blood group AB. All the patients were rhesus positive. Twenty-six patients (44.8%) were 
genotyped as RJRl, 25 (43.1%) were RIR2, 6 (10.4%) were Rlr and one (1.7o/o) was R2r. 
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Red cell alloantibodies were found in 5 of 58 patients (8.6%) and only one patient (1.7%) 
developed autoantibody. 
Alloimmunised patients 
Details of the patients with alloantibodies were shown in table 2. Tluee patients 
developed only I antibody, which were anti-E and anti-K respectively. One patient 
developed 2 antibodies, which was anti-E and anti-Jka and I patient developed 4 
antibodies, namely anti-E, -c, -S and -N. Time at the development of antibody ranged 
between after 8 to I 00 units of packed cell transfused. 
There's no significant association between formation of alloantibody with gender 
(p=O.l6), age at start of transfusion (p=0.58), nutnber of packed cell transfused (p=l.OO) 
and splenectomy (p=0.31 ). 
DISCUSSIONS 
To the best of our knowledge this is the first report on the incidence of RBC 
immunization atnong tnultiply transfused thalassaemic patients in Malay population. The 
frequency of alloimmunization ranged from about 5% to 30% in transfusion dependent 
• • 
56 7 1 1 1 . "d f RBC II . . . thalassaemta patients. · · r owever, t 1e tnct ence o a otnununtzatton and 
autoimmunization was low in this study, which was 8.6% and 1.7% respectively. This 
study was consistent with the study by Ho et al in I-long Kong.4 Alloin11nunization rate in 
study by Singer et al.3 and R ameen et al.2 were 22% and 30% respectively. The higher 
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alloimmunization rate in these two studies were probably due to the heterogeneity of the 
population living in Greece and Kuwait and mistnatched RBC phenotype between donor 
and recipients compared to our study population which are more homogenous. 
In the present study, anti E was seen most frequently followed by anti c (Rhesus 
system), anti S, anti N (MNSs system), anti Jka (Kidd system) and anti K (Kell system). 
All of our patients received con1patible blood for ABO and Rh D antigen. In an Italian 
study, the alloantibody was almost entirely confined to the common antigen of Rhesus, 
Kell, Kidd and Duffy systerns.6 Several studies shown that anti E are the most prevalent 
alloantibodies among transfusion dependant thalassaemia patients. 2• 4• 6 
Autoantibodies was found in an 11 years old post-splenectomy Malay girl with HB 
E/[3 thalassaemia. She developed autoantibody without underlying alloantibody as 
detennine by persistent positive direct Cootnbs test with no specific patten1 in· red cell 
elution test and panagglutination in absorption test. The monospecific direct Coombs test 
was positive for both lg G and C3d in this patient. No secondary causes were identified in 
this patient. Study in Kuwait observed that 11% of their patients developed autoantibody 
which positive for both lg G and C3d or lg G alone2• However, n1ajority of their RBC 
autoantibodies were associated with RBC alloantibodies. They reported that the presence 
of residual donor white blood cells (WBC) could have potential influenced on the rate of 
alloimmunization and autoimmunization seen among transfusion dependent thalassemic 
patients in Kuwait. RBC bound Ig G was found n1ore abundant in splenecton1ised than 
nonsplenectomised subjects in thalassemia patients8. The antibodies also were found to 
have specificity for spectrin and band 3 proteins in thalassaetnia patients. 
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Our results showed that there was no significant association between 
alloimtnunization and gender however; we observed that all of the alloirnnn~nized patients 
were fetnale. Only I of our alloin1munized patient was adult, and the alloimmunization in 
her could be due to previous pregnancy or blood transfusions. Clinically significant 
alloantibodies have been reported to occur about twice as often in women compared to 
men.9 Of the 5-alloitrununized patients in our study, 3 were adult and 2 were fron1 
paediatric age group. There's no association between alloimmunization and age 
demonstrated in this study. Few studies also reported that no significance relationship 
between age and alloimmunization in transfusion dependent thalassaemia patients 3•4•1 0• 
Adult recipients, aged 16 to 88 years, apparently do not lose their ability to respond to red 
cell alloantigens as they aged.9 
Our low alloimmunization rate in this study probably can be explained by the 
similarity in the ethnicity between patient and donor. All of our alloimmunized patients 
were Malays and n1ost of our blood donors were also Malays, which con1prised about 83%, 
of blood donors in our local population. In 1-Iong Kong majority of immunized patients 
were Southern Chinese and all blood donors were predominantly of the satne ethnic origin. 
Lower rate of alloimmunization in their study was explained by their access to 
phenotypically matched donors in Hong Kong.4 
We observed that all 5 of our immunized patients were started on transfusion after 
the age of one year old. llowever, our results showed there was no statistically significant 
association between alloimmunization rate and the age at start of transfusion. R ameen et 
al.2 found majority of alloitntnunised patients fonned first alloantibody between the aged of 
2 and I 0 years (58%). They observed that most of the alloimmunized patients involved in 
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their study deve1oped alloantibody at a younger age. Michail V et al. 7 , Singer et al.3 and T 
Spanos et al. 5 reported that low frequency of alloimn1unization fotu1d i~ patients with 
thalassaemia major who started transfusion early, result also supported the view that there 
was some form of immune tolerance induce by an immature itnn1une response mechanism 
to repeated blood transfusion. Immune response may also be affected by the patient's age at 
the start of transfusion and the number of blood units a patient receives. Despite exposure 
to many RBC and WBC antigen, infants do not produced alloantibody against blood cells 
• 11 
antigen. 
In our study we found that the earliest development of antibody was after 8 units of 
packed cell transfused. However there was no significant relation between nun1ber of 
packed cell transfused and alloimmunization rate (p > 0.05). T Spanos et a1.5 in their study 
found that the earliest sensitization appear after I 0 units transfusions. Blutnberg et al. 12 
conclude that most blood group antibody seen in multiply transfused patients were due to 
previous pregnancy and to the initial first ten transfusions. However, the number of 
antibody formation tends to increase with increasing number of transfusions. 
In our study, despite a higher rate of patients with splenectomy, none of them had 
alloantibodies. This was in contrast to Singer et al.3 observed that patient who had 
splenectomy had a higher alloimtnunization rate. The absence of spleen tnay further 
enhance the immune response to the infused foreign antigens, which are not affectively 
filtered .. 
In our study majority of the patients received packed cells aged between 2 to 7 days 
old. Frabetti et al. 13 noted that apoptotic was found to occur starting fron1 first 48 to 72 
hours of storage. 
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All of patients involved in this study had long·tenn exposure to non·leukodcpleted 
packed cells due to litnited budget. Study by Blutnberg et al. 14 suppot1 the. hypothesis that 
WBC reduction may be associated with a reduced frequency of RBC alloimmunization. 
However this result is in contrast with study by Uhlmann et al. 15 who observed that no 
significant difference in the transfusion reactions in patients receiving leucodepleted and 
non-leucodepleted RBC. Nuclear n1atrix protein that is released in the RBC unit frotn 
apoptotic white cells during cold storage, might induced antibody response in multiply 
fi d . 16 trans use patients . 
Our data show that the rates of RBC immunization to red cell antigens are low in 
transfusion dependent Malay thalassaemic patients despite the usage of non-leucodepleted 
blood. This probably can be explained by the homozygosity in ethnic between blood 
donors and thalassaernia patients and the usage of relatively fresh packed cells. We found 
that age at started of transfusion and splenectomy did not influence the forn1ation of RBC 
antibodies. 
Due to high incidence of anti E in our studied population, it is advisable to 
genotyped patients and matched red cell units for E antigen in addition to ABO and D 
antigen. Antigen matching transfusion will effectively prevent alloimmunisation for 
thalassaemia patients who have a life long transfusion dependent disease. 
10 
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Table 1 Demographic data of thalassaemia patients who received regular blood 
transfusions 
Demographic data 
Total patients 
Diagnosis 
8 Thalassaemia major 
HbE/8 thalassaemia 
Hb H Constant Spring 
Hb H disease 
Gender 
Male 
Female 
Splenectomy 
Yes 
No 
Number of patients (n) 
58 
8 
46 
3 
1 
34 
24 
15 
43 
14 
(%) 
13.8o/o 
79.3°/o 
5.2°/o 
1.7o/o 
25.8o/o 
74.2°/o 
··-----·---~---
Table 2 Data of patients with alloantibody 
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 
ABBREVIATIONS: RBC = red blood cell; WBC = white blood cell; lg = 
hnn1unoglobulin; l-Ib = haen1oglobin; Rh =rhesus; LISS = low ionic saline solution 
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ABSTRAK 
Salah satu daripada risiko kemasukan darah adalah pembentukan antibodi terhadap satu atau 
lebih antigen sel darah merah. Pembentukan antibodi terhadap sel darah asing atau antibodi 
terhadap sel darah sendiri akan merumitkan lagi rawatan kemasukan darah kepada pesakit 
thalassaemia yang memerlukan kemasukan darah yang bemlangkali. Maka, kekerapan. 
sebab-sebab dan cara mengatasi fenomena ini di kaji di kalangan pesakit ini. 
Data serologikal dan klinikal daripada 63 orang pesakit thalassaemia yang memerlukan 
kemasukan darah yang berulangkali , yang mendapatkan rawatan di Hospital Universiti Sains 
Malaysia dan Hospital Kota Bharu di kumpul dan di analisa secara prospektif. Sampel 
darah di analisa berdasarkan prosedur tabung darah yang standard untuk ujian saringan dan 
penentuan antibodi. 
Empat puluh sembilan (77.8%) pesakit adalah pasakit thalassaemia HbE/p, 10 (15 .9%) 
adalah thalassaemia P major, 3 (4.7%) adalah Hb II constant Spring dan 1 (1.6%) adalah 
pesakit Hb H. Kesemua pesakit menerima darah yang dilakukan ujian penyesuaian darah 
hanya untuk kumpulan darah ABO dan Rh (D) antigen sahaja. Kcseluruhmmya, 7.9% 
daripada pesakit menghasilkan antibodi terhadap sel darah asing dan 1.6% pesakit 
menghasilkan antibodi terhadap sel darah sendi ri. Tiga orang pesakit membentuk satu jenis 
antibody, seorang pesakit membentuk 2 jenis antibodi, dan seorang pesakit membentuk 4 
j enis antibodi. Antibodi yang di hasilkan adalah anti E, anti c, anti K, anti .lka, anti N dan 
anti S. Didapati tiada perkaitan di antara bangsa, splenektomi, kekerapan kemasukan darah 
IX 
dan umur semasa 1nula n1enerima ke1nasukan darah dengan pembentukan antibodi terhadap 
sel darah merah, mungkin disebabkan oleh saiz sampel yang kecil. Walaubagaimana pun 
didapati kesemua 5 pesakit yang menghasilkan antibodi terhadap sel darah asing menerima 
kemasukan darah yang pertama selepas berumur 1 tahWl dan tiada pesakit yang telah 
menjalani splenektomi. Dua puluh tiga orang pesakit didapati positive untuk. ujian 
antiglobulin Jangsung, dimana 2 orang pesakit menghasilkan lg G dan C3d dan 21 orang 
pesakit menghasilkan hanya lg G. 
Kesimpulannya, kemasukan darah yang sesuai adalah perlu untuk pesakit yang menerima 
pemindahan darah secara kronik untuk mengelakkan penghasilan antibodi terhadap sel darah 
asing. Memandangkan tingginya kekerapan penghasilan anti E, adalah di nasihatkan sel 
darah merah di sesuaikan untuk antigen E untuk. pesakit thalassaemia yang menerima darah 
berulangkali. Dengan itu juga, kesemua pesakit yang akan mulakan kemasukan darah 
seharusnya dilakukan ujian penentuan fenotip untuk antigen sel darah merah. 
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ABSTRACT 
One of the risks of blood transfusion was formation of antibodies against one or more red 
cell antigens. The developtnent of alloantibodies and autoantibodies complicates transfusion 
therapy in multiply transfused thalassaemia patients. Thus, frequency, causes and 
prevention of this phenomenon were studied among these patients. 
Clinical and serological data of 63 multiply transfused thalassaemia patients who sought 
their treatment in 1-Iospital Universiti Sains Malaysia and Hospital Kota Bharu were 
collected and analyzed prospectively. Blood samples were subjected to standard blood bank 
procedure for screening of antibody and subsequent antibody identification. 
Of these patients, 49 (77.8%) were l1b E/P thalassaemia, 10 (15.9%) were p thalassaemia 
major, 3 (4.7%) were l-Ib I-1 Constant Spring and one (1.6%) were l-Ib H disease. All 
patients received blood matched for only ABO and Rh(D) antigens. Overall, 7.9% of the 
patients had clinically significant alloantibodies and 1.6% had autoantibodies. Three 
patients develop one type of antibody, one patient developed 2 types of antibodies and one 
patient developed 4 types of antibodies. The specificities of the alloantibodies were anti E, 
anti c, anti K, anti Jka, anti N and anti S. There was no significance effects of ethilicity, 
splenectomy, frequency of transfusion and age at the start of transfusion on red cell 
immunization in this study due to small sample size. However we observed that all the 5 
patients that developed alloantibodies had their first transfusion after the age of one year old 
and none of them had undergone splenectomy. Twenty-three patients were positive for 
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direct antiglobulin test, of which 2 were positive for Ig G and C3d and 21 were positive for 
lg G only. 
As a conclusion, transfusion of matched blood was essential for chronically multi-transfused 
patients in order to avoid alloimmunisation. Considering the high frequency of anti E, it is 
advisable to match red cell unit for E antigens in multiply transfused thalassaemia patients. 
Therefore, all thalassaemia patients who had heed started on transfusions should have RBC 
antigen phenotyping. 
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GENERAL INTRODUCTION 
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1.0 GENERAL INTRODUCTION 
Thalassaemia is one of the major public health problems in Malaysia. It is a heterogeneous 
group of inherited autosomal recessive disorder of haemoglobin syntheses, which are 
characterized by the absence or reduced output of one or more globin chains of haemoglobin 
(George, 1998). 
Clinically thalassaemia are classified according to their severity into major, intermedia and 
minor fonns. Thalassaemia major is a severe transfusion dependent disorder. Thalassaemia 
intermedia are characterized by anaemia and splenomegaly and require non-regular 
transfusion. Thalassaernia minor is the symptomless carrier states (George, 1998). 
J3 thalassaemia are the most important types of thalassaemia because they are so com1non 
and produce severe anaemia in their homozygous and compound heterozygous state 
( Hoflbrand, 200 I). 
Present management consists of regular monthly b]ood transfusions to maintain the mean 
haemoglobin level of 10-11 g/dl and this remains the main treatment for severe thalassaemia 
(George, 1998). One of the complications of blood transfusion is the formation by the 
recipients of alloantibodies and autoantibodies against red blood cell antigen. Results from a 
number of studies had demonstrated various frequencies and percentages of alloantibody 
and autoantibody formation in transfused patients. Some alloantibodies were hemolytic and 
might cause hemolytic transfusion reactions and limit the availability of safe transfusion 
, 
while others were clinically insignificant. Red cell autoantibodies appeared less frequent but 
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could result in clinical haemolysis and difficulty in cross-matching blood (Singer et al., 
2000). Antibodies must systematically be identified in the recipient's serum before every 
transfusion so that cotnpatible blood could be provided. Otherwise problems might occur 
which sometimes could even threaten the patient's life (Spanos et a/.1990). Prevention of 
alloin1n1unisation ranged from provision of red blood cells tnatched for all major antigens 
associated with clinically significant antibodies to blood matched only for antibodies that 
had already been made. This was because the fact that n1any alloantibodies were not 
harmful and expensive prevention methods might therefore benefit only sotne patients 
(Singer et al, 2000). 
Antigen matching transfusion would effectively prevent alloimtntutisation. To do so, the 
patient's ABO, Rhesus, Kell, Kidd and Duffy systems should be typed at diagnosis or before 
institution of transfusion therapy. Blood to be transfused should always be tnatched at least 
with ABO, Rhesus and Kell systetn (1-Ioflbrand, 2001 ). 
I hope that this study will contribute to a better comprehension of the probletn and will help 
to find the ideal approach for future transfusion policy in our population. 
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LITERATURE REVIEW 
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2.0 LITERATURE REVIEW 
2.1 INTRODUCTION ON THALASSAEMIA 
2.1. 1 Definition 
Thalassaemia : a heterogeneous group of genetic disorders of hen1oglobin synthesis which 
result from a reduced rate of production of one or n1ore of the globin chains of hemoglobin. 
2.1.2 Background 
Thalassaemia is a common condition, particularly in the Mediterranean region and South 
East Asia. The word 'thalassaemia' is a Greek tenn derived from thalassa, which n1eans 
'the sea' referring to the Mediterranean, and emia 'related to blood'. The first description of 
thalassaemia is given to American paediatrician, Thomas Cooley in 1925 and it wa() 
identified as a distinct entity at about the same time by several Italian clinicians. 
Undoubtedly, Cooley was responsible for the first description of severe, life threatening 
form of thalassaemia., while the Italian workers described a rnilder variety of the condition. 
In Europe, Fernando Riette described Italian children with unexplained hypochron1ic 
1nicrocytic anaemia in almost the same year in which Cooley reported the severe form of 
anaemia. Wintrobe and coworkers in the United States reported a mild anaemia in both 
parents of a child with Cooley anaemia (Weatherall , 2001). Further cases were identified 
and the disorder was variously called splenic anaemia, erythroblastosis, Mediterranean 
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anaemia or Cooley's anaemia (Hoftbrand, 2001). The severe fonn then was labeled as 
thalassaemia major and the mild form as thalassaemia minor (Weatherall, 2001). 
Thalassaemia are a heterogeneous group of genetic disorders of haen1oglobin synthesis that 
resulted from a reduced rate of production of one or more globins chain (Hoftbrand, 2001 ). 
The term 'thalassaemia' used to describe a disorder with a significant decrease in the rate of 
synthesis of one or more globins chain (B.J Bain, 2000). The globin chain that is produced 
in excess is responsible for the ineffective erythropoiesis and shortened red cell swvival 
(Weatherall , 2001 ). Thalassaemia are divided into a, ~' o~ and ro~ according to which 
globin chain is produced but at a reduced rate (Hoffbrand, 2001 ). 
I-laemoglobinopathies might result from mutation of a globin gene (Barbara, 2000). 
Mutation of a ~ globin chain result in variant form of l-Ib A and mutation in a a globin chain 
resulted in variant form ofHb F, A and A2. Similarly mutations ofr and o genes resulted in 
mutant forms of lib F and A2 respectively. In some disorders there was both synthesis of 
structurally abnorn1al haemoglobin and a reduced rate of synthesis of the variant 
haemoglobin. This was the case with l-Ib 1-1 Constant Spring and I-Ib E, which could be 
referred as ' thalassaemic haen1oglobinopathies' (Barbara, 2000). 
2.1.3 Prevalence and Incidence 
Thalassaemia and related disorders are the most common genetic disorder seen in Malaysia. 
As in other parts of the South East Asia, a thalassaemia, P thalassaemia, haemoglobin E and 
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haemoglobin Constant Spring are widely prevalent. A cross sectional study of a Malay 
community in Tanjung Karang showed that out of 111 individuals screened for full blood 
cooot, reticulocytes stain, haetnoglobin electrophoresis, haemoglobin A2 and haemoglobin F 
estimation, 1 in 4 person carried one or more of these abnormal genes (Ainoon et al, 1994). 
About 4.5% of the people in Malaysia are heterozygous carriers for B thalassaemia. 
Couples who are carriers are at risk of producing a child with ~ thalassaemia major where 
affected births annuaJly would be 2.1/1000 (George et al, 2001). A Study done by George et 
a/., 1990 on Chinese in West Malaysia, found that there are 3-5% of the Chinese population 
that carry J3 thalassaemia trait which cause severe transfusion dependent in homozygous 
state, and when combined with haemoglobin E trait, also cause severe anaemia requiring 
long term n1edical support and regular blood transfusions. 
Thalassaemia major was seen in about 3% in the Singapore populations. l-Ib E trait was 
detected among Malays in Singapore and this accoooted for 5% of the total number of 
Malays studied. Based on a survey on random samples submitted for haemoglobin 
electrophoresis, the incidence of P thalassaemia trait in Singapore was 3o/o (Chan et al, 
2001). The overall incidence ofB thalassaemia was 1% for Chinese and 1.4% for Malays in 
Singapore (Chong et a/, 1984). 
Study by Fucheron et al., 2000 found that J3 thalassaemia, a thalassaemia, haemoglobin E 
and haetnoglobin Constant Spring are prevalent in Thailand. The frequency are 20%-30% 
for a thalassaemia, 3%-9% for J3 thalassaemia, 10%-50% for haemoglobin E and 1%-8% for 
haemoglobin Constant Spring. There is high prevalence of haemoglobin E in Thailand and 
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l--Ib E/f3 is the most comtnon ~ thalassaemia in this region. A similar finding among our 
Malay Kelantan population, from study by George et a/., 2001 showing the incidence of l-Ib 
E tha1assaetnia was 39%. 
A study on 450 healthy adults was conducted in Surabaya, Indonesia and found 4% of thetn 
are p thalassaen1ia trait, 6.2% had haetnoglobin E trait and 2.2% had a thalassaemia trait 
(Sandi, 1987). In Brunei a study was done on I 000 patient who was referred for low 
baetnoglobin, and/or low MCH and MHC. It was found that 30% of these patients are 
proved to have thalassaemia or haemoglobinopathy. ~ thalassaetnia was diagnosed in 22.7% 
and a thalassaemia was 4.3 % of this population (Ja')di, 1992). Distribution of l-Ib E and p 
thalassaemia in South East Asia was shown in figure 1. 
8 
(J 
Figure 1. Distribution of B thalassaemia and Hb E in South East Asia. 
(Reprinted fron1 Weatheral OJ, 1998). 
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2.2 COMPLICATIONS OF RED CELL TRANSFUSION 
2.2.1 Definitions 
Alloantibody: an antibody that is directed against an rbc antigen that is lacking on the 
patient's rbc. 
Autoantibody: an antibody that is directed against an rbc antigen that is on the patient's rbc. 
2.2.2 Haemolytic Transfusion Reactions 
Haen1olytic transfusion reactions are subdivided into 2 types, itnmcdiate and delayed. The 
most common cause of immediate haemolytic transfusion reactions ( IHTRs) results fron1 
the transfusion of ABO-incompatible rbc because of a clerical error in the labeling of the 
patient's cross-match specitncn (at the time of phlebotomy or in the blood bank) or the 
misidentification of the intended recipient at the titne of transfusion. Delayed haemolytic 
transfusion reactions (01-ITRs) is most often the result of an anamnestic response in a 
patients who was previously sensitized hy transfusion, pregnancy or transplant in whon1 
antibody was not detectable by standard pretransfusion methods (Patrice et al, 1994). 
1. Immediate Haemolytic Transfusion Reactions (IHTRs) 
11-ITRs represent the destruction of transfused donor red blood cells by an immunologically 
mediated mechanism. Factors that influence the severity of II ITRs aTe class and subclass of 
immunoglobulin, its ability to activate completnent, its plasn1a concentration, its avidity, its 
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specificity., red blood ce11 antigen density, activity of RES., sensitivity of rbc membrane to 
complement, the amount of incompatible red cell transfused and the thermal range of the 
antibody (Patrice et al., 1994). 
The reported incidence of II-ITRs reactions varies from 1 per 1 ,417 to 1 per 21 ,000 units 
transfused. The tnorlality rate of patients having IHTRs ranges from 7% to 40% (Patrice et 
al, 1994). 
The 11-ITRs generally result from the formation of Ig M antibody-rbc antigen complexes that 
induce complement-mediated intravascular lysis. The membrane-associated immune 
complex provokes dissen1inated intravascular coagulation by activating both the intrinsic 
coagulation pathway (via llageman factor and complement) as well as the extrinsic systen1 
(via platelet and leukocyte n1ediators). Concon1itantly, Hagetnan factor activates a 
vasomotor response 1nediatcd by the production of bradykinin. This leads to vasodilatation 
and increased capillary pen11eability resulting in hypotension. Recent evidence strongly 
supports the role of proinflammatory cytokines (glycopeptides produced by a number of 
cells including monocytes, macrophages, lymphocytes, and endothelial cells) as mediators 
of many of the systetnic effects of IHTR. Interleukin 1 p (IL-l ~), tumor necrosis factor a 
(TNF-a), and interleukin 6 (IL-6) have been shown to be secreted by leukocytes that have 
been exposed to antibody-coated rbcs. These substances arc known tncdiators of a shock-
like state with fever, rigors~ leukocyte and endothelial cell activation, and capillary leakage. 
Laboratory findings include haemoglobinuria., haemoglobinetnia and a positive OCT result. 
An eluate n1ade from the patient's rbcs will generally contain the pathogenic antibody. 
Management consists of imtnediate discontinuation of the transfusion, supportive rneasures 
ll 
aimed at restoring or rnaintaining systemic perfusion and urine output, and treating 
complications of disseminated intravascular coagulation, if present (Patrice et al, 1994). 
ii. Delayed Haemolytic Transfusion Reactions (DHTRs). 
There is increased incidence over time due to the introduction of tnore a sensitive 
technique for antibody identification and greater awareness of the syndrome. Fatality 
caused by DJITRs is rare (Patrice et al, 1994). 
Dl-ITRs occur as a result of an anan1nestic response from exposure to n1inor rbc antigens, 
typically those belonging to the Rh, Kell, Kidd, or Duffy blood groups. These reactions are 
not as severe as IHTRs and require a higher index of suspicion for diagnosis. The clinical 
picture is characterized by the onset of low-grade fever, jaundice, and a gradual decline in 
haemoglobin level 5 to 1 0 days following transfusion. In some cases haen1olytic occurs 
within 3-21 day time fran1e (Patrice et al, 1994). Haemolysis is typically extravascular with 
elevated indirect bilirubin and LOll levels. The DAT result is positive. Identification of the 
antibody is performed to provide antigen-negative rbcs for all subsequent transfusions. The 
course is self-Iin1ited, as the transfused allogeneic cells beco1ne Ig G sensitized and 
subjected to gradual clearance by the RES. Serologically these findings are consistent with 
a positive OCT caused by drug or hypergammaglobulinernia. Medication history and 
quantitation of serum immunoglobulin levels is needed to exclude the cause of the positive 
DA T. Mechanism by which these patients developed a positive l)J\ T remains unknown 
(Nancy et al, 1995). 
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HI. Delayed Serological Transfusion Reactions ( DSTRs) 
More often there is serological evidence of alloimmunisation (positive DAT and/or IAT) 
without clinical evidence of red cell destruction. This is called delayed serological 
transfusion reaction (DSTR). Nancy et al found that the rate of DSRT was most frequent. 
There was decrease in incidence of DHTRs and increase in DSTRs. These changes are most 
likely due to a cotnbination factors, including a decrease in average length of stay for in 
patients where the patients were discharged before the antibodies reached the threshold of 
the antibody detection system and the adoption of polyethylene glycol antibody detection 
system, which has been reported to be more sensitive than the albumin and papain technique 
(Pineda et a/, 1999). 
2.2.3 Iron Overload 
I-Iemosiderosis is a very real complication of repeated blood transfusions and cotnmonly 
seen in long term blood transfusion therapy. It is most conunonly seen in thalassaemia 
patients who commence transfusion early childhood. Each unit of blood ha') 
approxin1ately 200 mg of iron, while daily excretion rate is about 1 n1g. Iron chelating 
therapy does not completely overcome the iron load administered with blood, but has 
delayed the onset of problcrns due to haemosiderosis (Hoffl">rand, 2001 ). 
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2.3 RBC IMMUNIZATION IN THALASSAEMIA 
2.3.1 Introduction 
One of the complications of blood transfusion is the production of alloantibodies against 
red cell by the recipients. The results from a number of studies have demonstrated 
various frequency and percentages of alloantibody fonnation in transfused patients. 
These risks apply mainly to those patients who received multiple transfusions including 
those suffering from thalassaemia. Such antibodies must be systematically identified in 
the recipient's serum before every transfusion so that compatible blood can be provided. 
Otherwise probletns may occur which sometimes could even threaten the patient's life 
(Spanos et al, 1 990). 
Alloimmunisation may exist and not be recognized because 1) the serun1 is not examined 
at the appropriate time following antigenic challenge 2) the antibody strength is below 
the threshold for detection 3) the target cells do not possess the corresponding antigen 4) 
serologic test are not optin1al or 5) the itnmw1ity is cellular not hu1noral (Richard et a/, 
1989). 
Clinically significant rbc alloantibody in multiply transfused patients can pose major 
problems in long-tenn transfusion therapy. Traditionally the rate of alloinununization 
was thought to increase with the total quantity of blood transfused (Brantley et al, 1988). 
Blumberg eta/, (1984) found that rbc alloimmunization is tnost frequent during the first 
1 5 transfusions. They also suggested thalassaemia patients becon1e alloitnmunised to a 
particular antigen because of underlying capacity for imtnune response in the initial 
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exposures. Study done by Spanos et al., (1994) found that early onset of transfusion 
(age<3 years) is associated with lower frequency of alloantibody formation. When 
antibodies against high frequency antigens develop, it can be very difficult to find 
suitable blood donors. Most blood transfusion services match only red cell units for 
ABO and Rh antigens (Fluit at al, 1990). It has been advocated that patients with 
haemoglobinopathies and with aplastic anaemia should receive transfusion matched for 
minor blood group antigens such as those in the Rh, Kell, Duffy, Kidd and Lewis 
systems in an attctnpt to prevent alloimmunization (Blumberg at al, 1984). 
2.3 .2 Prevalence And Incidence 
Study done by Singer eta/., (2000) on 64 transfusion dependent thalassaen1ia patients of 
predominantly Asians descent in Oakland found that 14 patients developed 
alloanlibodies and 16 patients developed autoantibody. 
Comparative study of usual vs. better match progrrunmes by Michail et a/., (1987) in 
Greece found that a statistically significant difference does not exist in overall frequency 
of alloimmunization between unmatched (23.43%) and better 1natch ( 14.28%). 
There are overall 5.2% of thalassaemia major patients in Italy had clinically significant 
red cell alloantibody (Sirchia eta/, 1985). 
In llong Kong, Ho et al found that rbc alloimmunisation was 7.4% among Southern 
Chinese transfusion dependent thalassaetnia patients. 
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In Republic of China, 6% of Chinese patients who received multiple transfusions had rbc 
antibodies. Anti E, anti Mia and Anti c was the common alloantibody (Chow et a/, 
1994). 
Study on patients received blood n1atched for ABO, Rh and Kell systems from their first 
transfusion; the in1munization rate was very low (3.7%) (Spanos et al. 1990). 
2.3 .3 Alloimmunization 
Alloitnmunisation may result fron1 prior exposure to donor blood components. As an 
adverse effect of blood component transfusion, alloimmunisation is a significant 
complication. Even very small mnount of donor antigenic rbcs can elicit an alloimmune 
response. 
With first exposure to foreign antigen, lymphocyte 1nemory is invoked. This will result 
in a moderate production of Ig M and Ig G antibodies. Secondary exposure elicits rapid 
production of large amount of Jg G class antibody rising rapidly in the first two days 
after reexposure to the antigen. The antibody produced attaches to the antigenic surface 
and may interact with the co1nplen1ent system or RES. 
The factors for aJJoimmunization are complex and involved at least 3 main contributing 
elen1ents; the rbc antigenic difference between the blood donor and the recipient; the 
recipient immune status and immunotnodulatory effect of the allogenic blood transfusion 
or the recipient's inunune systen1 (Singer et al, 2000). 
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A low rate of nlloimmm1ization n1ay be expected when there is hon1ogeneity of rbc 
antigens between the blood providers and recipients (1-Io et al, 2001 ). Ramsey et al, 
( 1988) observed that. there is loss of red cell antibodies over time and patients under 20 
years of agewere more likely to Jose significant antibodies. Pretransfusion review of 
previous records is vital for the prevention of delayed haemolytic transfusion reactions, 
because of the high number of clinically significant antibodies that are undetected in 
subsequent routine screening. Anti Jka and anti C had particularly high frequency of 
loss while Kidd antibodies often disappear rapidly. Anti C alone without anti D was 
especially prone to subsequent loss (Ramsey et al, 1994). 
2.3.4 Autoimmunization 
Autoantibodies are directed against the individual own red cells. Most autoantibodies 
react with high incidence antigens; they agglutinate, sensitize the red blood cells of 
randon1 donors as well as those of antibody producers. This circulating hwnoral 
antibody may shorten red cell survival (Richard et al"' 1999). 
Autoantibody appears less frequent, but they can result in clinical haemolysis and 
difficulty in cross matching blood. Patient with autoantibody n1ay have higher 
transfusion rate and often require immunosuppressive drugs, splenecton1y or alternative 
treatments. Study done by Singer et al found that 16 patients with autoantibody are 
associated with the presence of alloantibody. Of these autoantibodies, eleven 
autoantibody were typed as Ig G and 5 were typed as lg M and 3 patients with this 
antibody developed clinically significant imn1une haemolytic anaetnia. 
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The pathogenesis of erythrocyte autoantibody formation following transfusions is not 
well understood. 1-Iowever it was suggested that alloantibody binding to the rbc could 
lead to confom1ational changes of the antigenic epitope that ultimately stimulate 
production of autoantibody (Sharon M et al, 1999). Sharon M et a/ found that it is 
possible that certain persons are genetic 'responders' who have an increased tendency to 
develop rbc autoantibody and the tendency toward autoantibody forn1ation could reflect 
an overall dysfunction of the inunune system. 
2.3 .5 Contributing Factors 
i. Age At Start Of Transfusion 
Immune response tnay be affected by patient's age at the start of transfusion. 
Transfusion at early age (<3 years) may offer some itnmune tolerance and protection 
against alloimmunization in thalassaemia patients (Singer et a!, 2000). 
Early onset of transfusion (age <3 years) is associated with lower frequency of 
alloantibody formation. In a study done by Spanos et a/, (1990) he observed that in 
whotn transfusion began before the age of 3 the alloimtnunization rate were lower than 
whom transfusion began after the age of 3. The resistance to alloimtnunization perhaps 
due to immaturity of the itnmunological syste1n. 
Sirchia et al, (1984) found that the rate of red cell alloantibodies was significantly lower 
in those less than 6 years of age. 
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Red cell antibodies were particularly likely to occur in patients who started regular 
transfusion late, so excessive hesitation about starting transfusion should be avoided 
(Rebulla, 1991 ). 
11. Phenotypic Rbc Matched Blood 
The highest rate of clinically significant alloimmunization occurred an1ong patients who 
were transfused with non-phenotypically matched blood (Ho el al, 2001). Spanos et al., 
(1994) found that there is statistically significant difference in the rate of 
alloimmunisation in patients who received con1patible blood not only for ABO and Rh D 
but also for CcEe and K antigen. They suggest that patients who will need tnultiple 
blood transfusions should receive blood matched for ABO, Rh D, Cc, Ee and K antigen. 
Matching for Rh and Kell system is essential since the antigens of these systems trigger 
the greatest percentage of alloimn1unisation. This policy and its application in 
multitransfused patients could overcharge the transfusion services with higher cost and 
perhaps little benefit. llowever extra expense involved in more con1plete blood 
matching is acceptable when weighed with the risk and problen1s entailed from 
transfusion of unn1atched blood. In order to decrease the screening volume on long-term 
basis, the researchers proposed the possibility of using blood fron1 known donors, 
matched for a single initial occasion for all future transfusion. 
Specificity of the alloantibody in thalassaemia patients were almost entirely confined to 
the common antigens of Rh, Kell, Kidd and Duffy systems. There was lower incidence 
of alloinunw1isation in centres, which followed the 'better match 'policy than with those 
' 
which do not. Prevalence of red cell alloimmunisation was lower in thalassaemia major 
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than in patients with other disease. This indicates that it is not useful to look for 
compatibility for antigen other than ABO and D. Effort should be redirected to ensure 
availability of enough available blood for immunized patients, especially those who have 
mixtures of red cell alloantibodies in their serum. All new patients should be typed for 
the common antigen of the Rh, Kell, Kidd and Duffy to ensure that multi in1munized 
patients received compatible transfusions (Sirchia et al, 1984). 
Transfusion with blood matched for Rh and K antigen resulted in significant difference 
in the alloinlfllunisation rate. Singer et al., (2000) observed that reduced new antibody 
formation in patients switched to or started in phenotypically matched blood. 
In llong Kong, anti K was not encountered in their patients. So they rarely need to 
transfuse K negative antigen matched blood. Only anti E has been reported to be 
clinically significant causing haetnolytic transfusion reaction in their patients (1-Io et a/, 
2001). 
Matching of transfusion for additional antigens could increase cost drrunatically. 
Blumberg recon1n1ends patients should generally receive red cells matched only for 
Rh(D) and ABO (Blumberg et al, 1984). 
iii. Frequency Of Transfusion 
Incidence of antibody formation increases with the number of transfusions. Small 
nutnber of transfusion needed to stimulate formation of anti K or anti E. It is advisable 
to match red cell units for the K and E antigens in patients at relatively high risk. Fluit et 
a/., ( 1990) found that mean number of transfusions before antibody fonnation was 25. 
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They observed that 36.4% of pati ents made the ir first antibody before or at 10111 
transfusion and 9 1% made the ir first antibody before or at 35111 transfusion. They also 
found that once a person is imtmmizcd, the risk o f making more than one antibody 
increases 2.7 fold . Neil Blumberg et a/., ( 1984) found that most blood group antibodies 
seen in multiply trans fused patients are due to the initial 1 to 10 transfusions. The rates 
of an ti body fo rmation per trans fusion actually decrease with increasing number of 
trans fusions. They observed that many indi viduals make that an ti body during the first 
few exposures to the appropriate antigen. 
There is no s ignificant difference by gender or age. indicating a similar pattern of 
antibody fo rmation within the sub samples of men and women and the separate age 
categories (Fiuit et al, 1990). 
IV. Presence or Spleen 
4..-
Prevalence and specific ity of alloantibody did not d iffer between patien t who had 
undergone splenectomy and those who had not (Sirchia et al. 1984). 
Singer at al found from their study that patients who had asplencctomy had a higher 
alloimmunisation rate. The absence o f spleen may further enhance the immune response 
to the infused fo reign antigens, which are not effectively filtered. Splenectomy may 
enhanced or promote an immune reaction as there is absence o f an efficient fi ltering 
system for removal of damaged rbc (S inger et al, 2000). 
Ho et a!., (200 1) observed that there is no increase in alloimmunisation rate in patients 
underwent splenectomy. 
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Blood requirement in non-splenectomised patients is on average over 30% higher than 
that of splenectornised patients (Rebulla et al, 1991). 
v. Donor Ethnicity 
Singer et al., (2000) found that there is antigenic difference between the white donors 
and Asian patients. 1-Iigh alloinununisation rate runong Asian patients in Greece because 
the majority of the donor population is white and the majority of blood recipients were 
Asians. This will result in significant difference in the rbc antigen distribution. 
Lower alloimmunisation rate in 1-Iong Kong is explained by their access to 
phenotypically matched donors in Hong Kong (Ho et al, 2001 ). 
Study done by Elliot el a/ on white patients with chronic anaemia and sickle cell 
anaemta patients who received long term transfusion demonstrated that 
alloimmunisation in the patients with sickle cell anaemia was due to antigen 
mismatching between a largely white donor population and blacks recipients. 
It is important to study carefully all pertinent data, including phenotypes frequency of 
the donor population and of the patients, before initiating an antigen-tnatching program 
(Tahhan et al, 1994). 
2.4 IMMUNOMODULATORY EFFECT OF BLOOD TRANSFUSIONS 
Blood transfusion can induce immunomodulation. Allogeneic blood transfusion 
generally caused up regulation of humoral immunity and down regulation of 
macrophage and T cell imtnunity. Recent investigations into the tnechanism of 
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allogeneic transfusion induced immunon1odulation suggested that altered cytokine 
regulation might contribute to down regulation of macrophage and T cell function and 
up regulation ofhun1oral hntnunity (KJ Kao, 2000). 
Allogeneic transfusions predominately favors a Th2 type of imtnune response 
(Blumberg et al, 1 990). ln1n1unosuppressions of white cells are well recognized in blood 
transfusion. Marked absolute lymphocytosis were seen predon1inantly in 
splenectomised patients with the use of both non-leucoreduced and leucoreduced blood. 
Lymphocytosis is the result of immunomodulatory effect of blood elen1ents, absence of 
spleen and recipients immune status. It was postulated that activated immune system 
increased the propensity to form antibodies (Singer et al, 2000). 
Ho et al., (200 1) observed that significantly lower alloantibody rate had resulted from 
the introduction of leucodepletion. 
Infants did not fonn alloantibody against rbc antigens following multiple transfusions 
given during the first 4 n1onths of life. It was proposed that neonatal patients do not 
form antibodies to rbc due to functionally immature T and B lyn1phocytes (Floss et al, 
1 985). 
Chronic transfusion therapy gives an effect on the distribution of lymphoid cell subsets 
in the peripheral blood of patients with thalassaemia major. T suppressor cells (CD 8) 
are markedly increased in thalassaemia patients who have received 300 or more 
transfusions. CD 4 cells were significantly lower than normal in spl~nectomised 
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patients. Transfusion of blood products tnay lead to decreased CD 4:CD 8 ratios (Robert 
eta/, 1985). 
2.5 RED CELL SEROLOGY TECliNIQUES 
2.5.1 Introduction 
Red cell antigen antibody reactions are usually detected by agglutination tests, in saline or 
macrotnolecular media, with or without unmodified or enzyme treated rbcs, and with or 
without the use of low ionic media, antiglobulin sera and potentiators. One of the most 
important factors affecting the accuracy of results is the reading of the reaction, especially 
when it is weak. To obtain good results, qualified person must examine the reaction within 
a short space of tilne, and, even then:- it is some times difficult to interpret. 
For maximum sensitivity in antibody detection, reagent rbc should have homozygous 
expression of the appropriate antigens (Rh D Cc Ee Jka Jkb Fya Fyb Ss) and cells should 
be used individually and not be pooled. Using such screening cells, antibody screening 
will detect 99.9% of atypical antibodies, those not detected having specificity for low 
frequency antigens. 
2.5.2 The gel microtubes 
The gel 1nicrotubes was presented in at Congress of the International Society of Blood 
Transfusion (ISBT) in 1988. This gel system is marketed in the lJK as DiaMed-ID 
systen1. 
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